Kolexia
Pottier Virginie Oncologie médicale
Pottier Virginie
Oncologie médicale
Centre Hospitalier de Lens
Lens, France
37 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de l'ovaire Trastuzumab Platine Bévacizumab Antinéoplasiques Récepteur facteur croissance Protéines de la famille de l'EGF Récepteurs ErbB

Collaborateurs

Voir plus
Stern-Ledieu Natacha
Stern-Ledieu Natacha
Selarl Groupe D'imagerie Medicale Et De Cancerologie Du Pont Saint Vaast, Lille, France
Giraud-Genouville Claire
Giraud-Genouville Claire
Cabinet libéral, Dechy, France
Spano Jean-Philippe
Spano Jean-Philippe
Hôpital Pitie Salpetriere, Paris, France
Tokarski Marc
Tokarski Marc
Centre Hospitalier de Lens, Lens, France

Industries

Voir plus
MSD
7 collaboration(s)
Dernière en 2023
Ipsen
4 collaboration(s)
Dernière en 2022
Lilly
4 collaboration(s)
Dernière en 2023
Sanofi
2 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years: An Open-Label, Randomized, Multicenter Phase III Study in Patients With HER2-Positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab
Essai Clinique (Roche)   03 septembre 2020
KALICOU3: Evaluation of the Impact of Emotional Skills of Young Women (≤ 45 Years), With Non-metastatic Breast Cancer, and Their Partner on Adjustment to Cancer
Essai Clinique (Centre Oscar-Lambret)   24 juin 2019
Results of the VENUS study: Bevacizumab efficacy and safety in platinum-sensitive recurrent ovarian cancer (OC)—A real-life ambispective study.
2019 ASCO Annual Meeting I   26 mai 2019
Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.
European journal of cancer (Oxford, England : 1990)   23 juin 2017
Preliminary results of the VENUS study: Bevacizumab efficacy and safety in recurrent, platinum-sensitive ovarian cancer—A real-life ambispective study.
2017 ASCO Annual Meeting I   30 mai 2017
Patient preference of trastuzumab administration (SC versus IV) in HER2-positive metastatic breast cancer: Results of the randomised Metaspher study
Abstract Book of the 41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmark   01 octobre 2016
{{person.lastact7.name}}
{{person.lastact7.jour}}   {{person.lastact7.date}}
{{person.lastact8.name}}
{{person.lastact8.jour}}   {{person.lastact8.date}}
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}